Methods and compositions for reducing vancomycin-resistant Enterococci infection or colonization
AssigneeMemorial Sloan Kettering Cancer Center
InventorsEric Pamer, Peter McKenney, Silvia Caballero
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.
Claims19
A method for reducing the risk of vancomycin-resistant Enterococci (VRE) infection or VRE colonization in a subject, and/or increasing resistance to VRE infection or VRE colonization in the subject, and/or reducing the severity of VRE infection in the subject, and/or reducing the amount of VRE colonizing the subject, comprising administering, to the subject in need of such treatment, a therapeutically effective amount of a composition comprising a Clostridiales VE202-05 bacteria and at least one of a Clostridium scindens bacteria and/or a Blautia producta bacteria, wherein the composition is administered to the subject by a gastrointestinal administration.
Dependencies are inferred from the claim text.